Abstract:Abstract Myelodysplastic syndromes (MDS) frequently progresses to acute myeloid leukemia (AML). Mechanisms underlying MDS transformation remain unclear. We showed that TET2 deficiency enhances MDS maintenance (PMID: 30146412). Besides frequent mutated in MDS/AML, TET2 levels were decreased during MDS progression (PMID: 23827711). Recently, we analyzed a dataset (GSE19429) and found lower TET2 levels correlated with shortened survival of patients with high-risk MDS. We thus assessed TET2 function in MDS leukemia transformation by deleting TET2 in a NHD13 knock-in mouse model, in which ~30% of mice develop AML. Therefore, we crossed conditional TET2-KO mice with NHD13 transgenic mice. NHD13/TET2-KO (NT) mice developed leukemia with shorter survival than did NHD13/TET2-WT (ctrl) mice (median days, NT: 219 vs. ctrl: 366, n=12, p<0.01). Half of the NT mice developed AML in 30 weeks, while ctrl mice did not. At 20th weeks (pre-leukemia stage), NT mice exhibited splenomegaly and hyper-cellular bone marrow (BM). Flow cytometry analysis of NT BM cells revealed increased lin-c-kit+sca-1- (LK) BM subset (LK%, NT: 3.89% vs. ctrl: 1.96%, n=12, p<0.01) and decreased apoptosis (AV+%, NT: 2.85% vs. ctrl: 7.59%, n=12, p<0.001). To search for acquired genetic lesions due to TET2-KO, we performed whole-exome sequencing of c-kit+ cells from pre-leukemic NT vs. ctrl mice. We focused on mutations newly acquired or those with increased variant allele frequency (VAF, fold change>2) in NT mice and ranked them based on their association with AML prognosis using PRECOG (http://precog.stanford.edu). We selected top three candidates SETD2, ARIH2, TET3 for further analysis. ChIP-qPCR revealed increased 5hmC modification at the mutant loci of these genes, consistent with a finding that the genomic regions with increased 5hmC modification are more subjective to occur mutations (PMID: 28440315). TET3 and SETD2, as tumor suppressors, exhibit frameshift-deletion. ARIH2 represents a single-nucleotide variant (ARIH2K440N). To test if ARIH2 loss-of-function accelerates proliferation, we transduced NHD13 c-kit+ cells with shARIH2 and performed CFC analysis. ARIH2 knockdown increased colony number relative to ctrl (shARIH2: 163±3.7 vs. shCtrl: 95±1.7, n=3, p<0.01). To assess ARIH2K440N function we constructed the corresponding human mutation ARIH2K441N as well as ARIH2R484I, seen in a patient with MDS (PMID: 19620960). We genetically deleted endogenous ARIH2 of K562 cells, then transfected with exogenous ARIH2-WT or ARIH2 mutants respectively. Unlike ARIH2-WT, ectopic expression of ARIH2K441N or ARIH2R484I blocked FGFR1 ubiquitination and degradation, activating STAT5, AKT and ERK1/2 signaling, suggesting that TET2 loss leads to secondly hits, which activate proliferation/survival signaling. Taken together, our finding provides a rationale for enhancing TET2 function to block MDS-malignant transformation. Citation Format: Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He, Haojie Dong, Yuhui Wu, Hanying Wang, Zheng Li, Victor Huang, Samer Khaled, Ling Li. TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2934.

Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia

Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia.

Mbd2 Ablation Impairs Lymphopoiesis And Impedes Progression And Maintenance Of T-All

Overexpression and Biological Function of MEF2D in Human Pancreatic Cancer.

Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion

MEF2D Functions as a Tumor Suppressor in Breast Cancer

MEF2C Opposes Notch in Lymphoid Lineage Decision and Drives Leukemia in the Thymus

Genetic and Clinical Characteristics of Acute B-cell Lymphoblastic Leukemia with MEF2D Fusions and Report of Two Novel MEF2D Rearrangements

Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells

The Positive Feedback Loop of MAD2L1/TYK2/STAT3 Induces Progression in B-cell Acute Lymphoblastic Leukaemia.

Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia

Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) is Associated with Poor Prognosis in Pediatric B Lineage Acute Lymphoblastic Leukemia.

Suppression of Mir-708 Promotes DKK3 to Inhibit Wnt/β-Catenin Signaling Pathway in Adult B-ALL

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia

HDAC2-miR183-5p Epigenetic Circuit Contributes to the Growth of Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia via PTEN/AKT and c-MYC Signaling Pathway

Loss of MBD2 Attenuates MLL-AF9-driven Leukemogenesis by Suppressing the Leukemic Cell Cycle Via CDKN1C

Retracted: EBF1 Gene Promotes the Proliferation and Inhibits the Apoptosis of Bone Marrow CD34+ Cells in Patients with Myelodysplastic Syndrome Through Negative Regulation of Mitogen‐activated Protein Kinase Axis

Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP‐IGH fusion gene